Drug
Gsk256066
Gsk256066: highest development phase Phase 2, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| GSK256066 NCT00612820 | Phase 2 | Rhinitis, Allergic, Seasonal |
Latest
No recent events.
Follow Gsk256066 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.